Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic

• A Drosophila Ras-Pten lung cancer model was established
• Altering cancer genes in the trachea led to growth and migration defects
• Screening identified trametinib plus fluvastatin as a candidate therapeutic cocktail
• Trametinib/fluvastatin showed synergistic efficacy in human lung cancer cell line

SummaryWe have developed a Drosophila lung cancer model by targeting Ras1G12V—alone or in combination with PTEN knockdown—to the Drosophila tracheal system. This led to overproliferation of tracheal tissue, formation of tumor-like growths, and animal lethality. Screening a library of FDA-approved drugs identified several that improved overall animal survival. We explored two hits: the MEK inhibitor trametinib and the HMG-CoA reductase inhibitor fluvastatin. Oral administration of these drugs inhibited Ras and PI3K pathway activity, respectively; in addition, fluvastatin inhibited protein prenylation downstream of HMG-CoA reductase to promote survival. Combining drugs led to synergistic suppression of tumor formation and rescue lethality; similar synergy was observed in human A549 lung adenocarcinoma cells. Notably, fluvastatin acted both within transformed cells and also to reduce whole-body trametinib toxicity in flies. Our work supports and provides further context for exploring the potential of combining statins with MAPK inhibitors such as trametinib to improve overall therapeutic index.

Graphical AbstractFigure optionsDownload as PowerPoint slide